Anil Parwani, MD, PhD, discusses the use of artificial intelligence technology to enhance cancer diagnostics and treatment.

The phase 3 KEYNOTE-867 and KEYNOTE-630 studies will be stopped due to futility, following analysis from independent data ...

In this episode of Emerging Experts, Paolo Tarantino, MD, discusses the latest developments in breast cancer research and ...

The phase 3 SOHO-02 trial has enrolled its first patient with advanced non–small cell lung cancer harboring activating HER2 ...

NXP800 was granted orphan drug designation from the FDA in ARID1a-deficient ovarian, fallopian tube, and primary peritoneal ...

In an interview, Anil Parwani, MD, PhD, discussed how artificial intelligence can be used in medical education and training, ...

BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in ...

Renal cell carcinoma specialists continue analyzing the case of a 61-year-old patient with indolent metastatic clear cell RCC ...

CDx, an investigational PET imaging agent designed to differentiate progressive or recurrent glioma from treatment-related ...

Clinicians discuss personalized approaches to initiating and adjusting luspatercept dosing, considering individual patient ...

Data from the phase 2 ReNeu study presented at the 2024 ASCO Annual Meeting support this priority review designation.

New data on zongertinib for HER2-positive non–small cell lung cancer will be presented at the IASLC 2024 World Conference on ...